Two-week interruption in methotrexate treatment versus treatment continued as usual and COVID-19 booster immunity in adults with inflammatory conditions (VROOM study): a randomised open label, superiority trial
Abhishek A., Boyton R., PECKHAM N., McKnight Á., COATES L., Bluett J., BARBER V., CURETON L., Francis A., APPELBE D., ELDRIDGE L., JULIER P., Valdes A., Brooks T., ROMBACH I., Altmann D., Nguyen-Van-Tam J., Williams H., COOK J.